Clinical trials, especially those targeting treatments for advanced solid tumors, are closely watched by investors for their potential to significantly impact a biotech company's valuation. The initiation of this trial indicates progress in Nuvation Bio's pipeline, which could lead to increased investor confidence and a positive impact on the stock price in the short term.